Basic Information
| LncRNA/CircRNA Name | LOXL1-AS1 |
| Synonyms | NA |
| Region | GRCh38_15:73908071-73928248 |
| Ensemble | ENSG00000261801 |
| Refseq | NR_040066 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | doxorubicin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qRT-PCR , Microarray , Western blot etc. |
| Sample | A normal prostate cell line RWPE-1 (ATCC, Manassas,VA) ,human prostate cancer cell line DU-145 |
| Expression Pattern | down-regulated |
| Function Description | lncRNA LOXL1-AS1 and EGFR were both downregulated, while miR-let-7a-5p was upregulated in doxorubicin-resistant prostate cancer DU-145 cells.MiR-let-7a-5p could target both lncRNA LOXL1-AS1 and EGFR to affect PCa progression. Upregulation of lncRNA LOXL1-AS1 promoted cell proliferation and migration, while suppressed cell apoptosis.Silence of lncRNA LOXL1-AS1 inhibited the tumor growth in vivo in DU-145 cells. |
| Pubmed ID | 31188543 |
| Year | 2018 |
| Title | LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related Pathway Regulates the Doxorubicin Resistance of Prostate Cancer DU-145 Cells |
External Links
| Links for LOXL1-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |